Abstract
Jodantipyrin or 4-iodo-1,5-dimethyl-2-phenyl-pyrazol-3-one is an iodinated form of antipyrine which belongs to the group of non-steroidal anti-inflammatory drugs. The parent compound, antipyrine, is keto derivative of pyrazoline and is the oldest known synthetic drug. The primery pharmacological activity of Jodantipyrin is based on its properties to induce endogenous type 1 interferons. The anti-inflammatory action of Jodantipyrin produces several effects such as reduction of degranulation of the mast cells; suppression of prostaglandins and arachidonic acid synthesis; cell membrane stabilizing activity; normalization of liver damage associated enzymes such as ALT and AST; lower intensity of oxidation and phosphorylation processes. Discovered direct antiviral activity is evidenced by suppression of viral DNA and RNA synthesis in vitro and under detail investigation in vivo. Jodantipyrin displays antiviral activity against interferon sensitive viruses including tick-borne encephalitis virus; hantavirus; influenza type A virus; herpes viruses; hepatitis B and C (HBV and HCV) viruses; Coxsackie A and B enteroviruses; papilloma virus and some others. Jodantipyrin was approved in Russia and neighboring countries for prevention and combinational treatment of tick-borne encephalitis (TBE) in 1996, combinational treatment hemorrhagic fever with renal syndrome (HFRS) in 2001, and later for prevention of seasonal flu. The most recent data suggests that Jodantipyrin might be effective against highly pathogenic avian influenza or bird flu virus. As the unique anti-viral therapeutic, Jodantipyrin is under intensive investigation as a potentially effective agent with a specific antiviral activity.
Keywords: acute renal failure and hemorrhage, tick-borne encephalitis, immunoglobulin, influenza, CHRONIC HEPATITIS B
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Antiviral Activity of Jodantipyrin – An Anti-Inflammatory Oral Therapeutic with Interferon-Inducing Properties
Volume: 7 Issue: 2
Author(s): Evgeni V. Schmidt, Elena A. Kropotkina, Gulnara A. Abdulova, Ekaterina V. Vlasova, Konstantin K. Raevski, Felix I. Ershov, Marina V. Mezenzeva, Dina Kh. Khunafina, Nina V. Krilova, Vladimir N. Khudoley, Marina A. Vnushinkaia, Elvira I. Beloborodova, Albina D. Pomogaeva, Elena V. Portnyagina, Alexandr N. Evstropov, Valentina E. Yavorskaya, Alexei V. Lepekhin and Albert S. Saratikov
Affiliation:
Keywords: acute renal failure and hemorrhage, tick-borne encephalitis, immunoglobulin, influenza, CHRONIC HEPATITIS B
Abstract: Jodantipyrin or 4-iodo-1,5-dimethyl-2-phenyl-pyrazol-3-one is an iodinated form of antipyrine which belongs to the group of non-steroidal anti-inflammatory drugs. The parent compound, antipyrine, is keto derivative of pyrazoline and is the oldest known synthetic drug. The primery pharmacological activity of Jodantipyrin is based on its properties to induce endogenous type 1 interferons. The anti-inflammatory action of Jodantipyrin produces several effects such as reduction of degranulation of the mast cells; suppression of prostaglandins and arachidonic acid synthesis; cell membrane stabilizing activity; normalization of liver damage associated enzymes such as ALT and AST; lower intensity of oxidation and phosphorylation processes. Discovered direct antiviral activity is evidenced by suppression of viral DNA and RNA synthesis in vitro and under detail investigation in vivo. Jodantipyrin displays antiviral activity against interferon sensitive viruses including tick-borne encephalitis virus; hantavirus; influenza type A virus; herpes viruses; hepatitis B and C (HBV and HCV) viruses; Coxsackie A and B enteroviruses; papilloma virus and some others. Jodantipyrin was approved in Russia and neighboring countries for prevention and combinational treatment of tick-borne encephalitis (TBE) in 1996, combinational treatment hemorrhagic fever with renal syndrome (HFRS) in 2001, and later for prevention of seasonal flu. The most recent data suggests that Jodantipyrin might be effective against highly pathogenic avian influenza or bird flu virus. As the unique anti-viral therapeutic, Jodantipyrin is under intensive investigation as a potentially effective agent with a specific antiviral activity.
Export Options
About this article
Cite this article as:
Schmidt V. Evgeni, Kropotkina A. Elena, Abdulova A. Gulnara, Vlasova V. Ekaterina, Raevski K. Konstantin, Ershov I. Felix, Mezenzeva V. Marina, Khunafina Dina Kh., Krilova V. Nina, Khudoley N. Vladimir, Vnushinkaia A. Marina, Beloborodova I. Elvira, Pomogaeva D. Albina, Portnyagina V. Elena, Evstropov N. Alexandr, Yavorskaya E. Valentina, Lepekhin V. Alexei and Saratikov S. Albert, Antiviral Activity of Jodantipyrin – An Anti-Inflammatory Oral Therapeutic with Interferon-Inducing Properties, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (2) . https://dx.doi.org/10.2174/187152308784533195
DOI https://dx.doi.org/10.2174/187152308784533195 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Use of Fusion Proteins and Procaryotic Display Systems for Delivery of HIV-1 Antigens: Development of Novel Vaccines for HIV-1 Infection
Current HIV Research Isatin Derivatives and Their Antiviral Properties Against Arboviruses: A Review
Mini-Reviews in Medicinal Chemistry Delivery Systems for Applications in siRNA Technology
Drug Delivery Letters Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS
Current Neuropharmacology A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Immune Restoration Disease: A Consequence of Dysregulated Immune Responses After HAART
Current HIV Research Antifungal Therapy Used in Central Nervous System Fungal Infections
Central Nervous System Agents in Medicinal Chemistry Chemokines and Malaria Infection
Current Immunology Reviews (Discontinued) Emerging Evidence for Neuropsycho-Consequences of COVID-19
Current Neuropharmacology University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures and Neuropathology
Current Alzheimer Research The Importance of Precise Documentation of Vaccination by Physicians and Vaccine Providers
Current Drug Safety Immune Response to Herpes Simplex Virus and γ134.5 Deleted HSV Vectors
Current Gene Therapy Hashimoto’s Encephalopathy Presenting as Recurrent Brief Psychotic Episodes in a 13-Year-Old Girl: A Case Report
Adolescent Psychiatry Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Epitope-Driven TB Vaccine Development: A Streamlined Approach Using Immuno-Informatics, ELISpot Assays, and HLA Transgenic Mice
Current Molecular Medicine Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Manipulation of Dendritic Cells for Tumor Immunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry